Adma Biologics Profit Margin

Adma Biologics posts a profit margin of 32.98% as of June 2026. That compares with 44.06% in the prior-year period — down 25.1% year over year. That is above the Healthcare sector average of 21.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Adma Biologics's profit margin was 44.06%. The latest reading is 32.98% — a 25.1% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 21.34% is typical. Adma Biologics's 32.98% is higher that level. That is roughly 54.6% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Adma Biologics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 32.98% as of June 2026; use YoY and peer views to separate noise from signal.

Context for ADMA's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.34%), and (3) consistency with growth and profitability. This page covers the first two; Adma Biologics's other metric pages and overview cover the third.